Physician profile
William Richter
NPI 1679816094
$3,565.41
in general payments reported to CMS, 2019-2025
31 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $19.46 · 2021: $370 · 2022: $581 · 2023: $977 · 2024: $684 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.44 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $681.66 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $413.50 | 2022-2025 | Breztri, Fasenra, Airsupra |
| Insmed, INC. | $365.36 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $327.83 | 2021-2025 | |
| Amgen INC. | $217.92 | 2022-2025 | Tezspire |
| Electromed, INC. | $207.41 | 2021-2024 | Smartvest |
| Grifols USA, LLC | $178.96 | 2021-2025 | Prolastin-C Liquid |
| Shionogi INC | $149.50 | 2024-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.84 | 2022-2023 | Spiriva Respimat, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $98.48 | 2022-2025 | Glassia |
| Harmony Biosciences LLC | $96.69 | 2021-2025 | |
| Mylan Specialty L.P. | $67.66 | 2021-2023 | Yupelri |
| Baxter Healthcare | $63.56 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $52.99 | 2021-2023 | Tyvaso |
| Genentech USA, INC. | $52.70 | 2022-2023 | Xolair |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $50.00 | 2022-2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $47.30 | 2024 | Lumryz |
| Vifor Pharma, INC. | $43.66 | 2024-2025 | Zemaira |
| Jazz Pharmaceuticals INC. | $38.88 | 2021 | |
| Lilly USA, LLC | $36.65 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $36.43 | 2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $34.11 | 2023-2025 | |
| Monaghan Medical Corporation | $31.12 | 2024 | Aerobika |
| Teva Pharmaceuticals USA, INC. | $26.17 | 2022 | |
| Merck Sharp & Dohme LLC | $26.06 | 2025 | Zerbaxa |
| Biogen, INC. | $24.43 | 2025 | Spinraza |
| Optinose US, INC. | $24.19 | 2024 | |
| Philips North America LLC | $18.39 | 2022 | |
| Vapotherm INC | $17.50 | 2022 | |
| Resmed Corp | $17.13 | 2021 | |
| Viatris Specialty LLC | $14.33 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.